A second randomized clinical trial has confirmed what the first one found — adding Avastin to standard chemotherapy does not reduce recurrences after surgery for stage III colon cancer.
The AVANT trial compared standard FOLFOX chemotherapy to either FOLFOX plus Avastin® (bevacizumab) or XELOX plus Avastin. Chemo was given for 6 months, and Avastin was added during that time and for another 6 months after chemo ended. Nearly 2,870 stage III patients took part in the study.
Like in the C-08 trial, there was a temporary benefit during the year that patients got Avastin, but it didn’t last. By the end of three years the percentage of people who were alive and cancer-free was slightly less in the two Avastin arms. Read the rest of this entry »